速递|信达生物:小分子GLP-1申报临床

GLP1减重宝典
21 Jul

整理 | GLP1减重宝典内容团队2025年7月16日,信达生物研发的IBI3032新药临床试验申请已获得国家药品监督管理局(NMPA)受理。信达生物官网显示,玛仕度肽是其在减重和血糖控制领域推进最迅速的候选产品。与此同时,公司还积极推进下一代GLP-1类药物研发,拓展创新治疗路径:IBI3032:一种口服GLP-1小分子候选药物。临床前数据显示,其在相同剂量下的生物利用度为同类产品的5至10倍。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10